Amsterdam, The Netherlands, June 13, 2017 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Euronext Brussels: KDS), a clin­i­cal stage bio­phar­ma­ceu­ti­cal com­pa­ny devel­op­ing inno­v­a­tive prod­ucts to make bone mar­row trans­plan­ta­tions for patients suf­fer­ing from blood can­cers and inher­it­ed blood dis­or­ders safer and more effec­tive, today announces that it has raised €5 mil­lion in gross pro­ceeds through a pri­vate place­ment (the “Transaction”) of new shares (the “New Shares”) com­plet­ed pri­or to the open of the mar­ket today.
The Company has placed 746,269 New Shares with a small group of exist­ing and new insti­tu­tion­al investors at a price of €6.70 per New Share, which rep­re­sents a 11% dis­count to the clos­ing price of June 12, 2017. The New Shares rep­re­sent 5.3% of the cur­rent num­ber of out­stand­ing shares (pre-Transaction) and will bring the total num­ber of shares (post-Transaction) to 14,712,770. In addi­tion, the investors have received 746,269 5-year war­rants enti­tling them to sub­scribe for 746,269 new Company shares at a war­rant exer­cise price of €7.70 (the exer­cise price being sub­ject to adjust­ment in case of cer­tain cor­po­rate and dilu­tive events).
The New Shares will be admit­ted to trad­ing on Euronext Amsterdam and Euronext Brussels fol­low­ing their issuance, which is expect­ed to take place on June 15, 2017.
Kiadis Pharma will use the net pro­ceeds of the Transaction to advance the clin­i­cal devel­op­ment of the Company’s ATIR prod­ucts and for gen­er­al cor­po­rate pur­pos­es.
Arthur Lahr, Chief Executive Officer of Kiadis Pharma, com­ment­ed: “Having recent­ly filed a Marketing Authorization Application for ATIR101TM with EMA, the Company con­tin­ues to make good progress regard­ing the Phase III tri­al and prepar­ing for EU com­mer­cial­iza­tion. We exe­cut­ed this pri­vate fundrais­ing to quick­ly aug­ment our cash posi­tion while we work on broad­er fund­ing ini­tia­tives. In this Transaction, we are pleased to see exist­ing share­hold­ers increas­ing their hold­ings, and wel­come new spe­cial­ist health­care investors.
Chardan act­ed as Sole Bookrunner and Placement Agent for the Transaction. Saola Healthcare Partners act­ed as finan­cial advi­sor to Kiadis Pharma.

Leave a Reply

Your email address will not be published. Required fields are marked *